Recent Advances in Biotherapies

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across bio-therapies. Monoclonal antibody therapies and siRNA therapies, constitute some examples of the profiled technologies, companies, and university. The corresponding clinical trial scenario is depicted, along with the industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternati

Table of Contents

Recent Advances in BiotherapiesTechnological Innovations in BiotherapiesTREMFYA™, Monoclonal Antibody Therapy for Plaque Psoriasis, Receives US FDA ApprovalsiRNA for Acute Kidney Injury Prophylaxis Demonstrates Favorable Results in Phase 2 StudyUS Patent Awarded for Novel Automated Cell Processing Platform DNA Sunscreen for Preventing UV-Induced Skin DamageClinical Trial Analysis and Industry InteractionsSummary of On-going Clinical Studies for GuselkumabKey Contacts

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.